Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Actually, after revisiting the CC, I see the total market around 80M for Evomela. Kurt G said

We did see some stocking at hospitals based on initial orders from a few customers which is estimated at 2 million to 3 million of the 9.4 million in reported EVOMELA sales.

So let’s say 2.4M in sales was stocking of product bringing the stuff they actually used around 7M. At 35% of the market that translates into about $80M. Forecasting based on number of centers targeted may not be a credible forecasting method but it puts you in the ballpark so based on the last 2 Qtrs I’m seeing another 18.6% increase in sales to 8.3M (7M*7m/5.9m [or 1.186] =) plus more stocking of initial orders of 2.5M to ~$10.8M in sales next Qtr. A question was asked from Swayampakula Ramakanth of HC Wainwright

Good afternoon Dr. Raj. Couple of quick questions but these are going to be more on EVOMELA. It's good to see that the EVOMELA is taking off the way it has. And we understand that there is a little bit of us talking which had happened in the fourth quarter. Are there certain bulk orders as well and on top of that you said that you're having 35% of the market at this point, do you think there is some expansion of the market happening at the same time?
Rajesh C. Shrotriya
RK first of all thank you for your question and I will have Kurt answer the question and then Tom.

Kurt A. Gustafson
Yes, so RK good question, maybe I should have made it clear in our comments. The way we're reporting sales right now is only on sales to end users. So there -- we don't report on sales to the wholesalers so we actually have I think about $2 million in deferred revenue for sales that were to the wholesalers but not to the end user. So we're not reporting any sales that relate to stocking at wholesalers. The stocking that I was talking about was at a few large hospitals who are the end users. And Tom maybe you can talk about the market.

Thomas J. Riga
RK we're ecstatic with the launch of EVOMELA. I think in eight months to have exit shares north of 35% and reporting sales that you saw at 9.4 million. Even if we back out some of the purchases made at the larger institutions which ultimately are still demand units. We’re thrilled with what we're seeing in the market. And for me commercially I think it's a good signal to see the team perform in a highly competitive market that as I think about the promising pipeline ahead it just gives me more confidence and more bullish about the team that we have on the field.